Dentsply Sirona recently reported second-quarter 2026 results showing a 4.1% year-over-year net sales decline but a return to net income, with higher margins and stronger cash generation, and also confirmed it will present at the Baird 2026 Global Healthcare Conference on September 15, 2026.

The combination of improved profitability and cash flow, despite weaker revenue and a history of pressure on returns, led management to reiterate full-year 2026 guidance, highlighting a sharper focus on efficiency and margin quality.

We'll now assess how Dentsply Sirona's return to profitability and reaffirmed full-year outlook may influence its investment narrative and risks.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

DENTSPLY SIRONA Investment Narrative Recap

To own Dentsply Sirona, you need to believe that its push into higher-margin digital dentistry and tighter cost control can offset ongoing revenue pressure and past return issues. The latest quarter's margin recovery and cash flow strength modestly support that view, but soft top-line trends leave the near term still driven by proof that sales can stabilize. The biggest risk remains that volume and pricing pressure in key elective categories persist, muting the impact of efficiency gains.

The reiterated 2026 guidance of US$3.5 billion to US$3.6 billion in net sales and adjusted EPS of US$1.40 to US$1.50 is the announcement that most directly ties into this earnings release. Holding the outlook steady, despite a 4.1% sales decline, frames cost programs and digital initiatives as the main short term catalyst, while also testing whether management can rebuild credibility after years of weaker profitability and write downs.

Yet behind the improving margins, investors should still be aware of lingering impairment and capital allocation questions that could...

Read the full narrative on DENTSPLY SIRONA (it's free!)

DENTSPLY SIRONA's narrative projects $3.8 billion revenue and $189.7 million earnings by 2029. This requires revenue to remain fairly flat each year and a $817.7 million earnings increase from -$628.0 million today.

Uncover how DENTSPLY SIRONA's forecasts yield a $13.40 fair value , a 17% upside to its current price.

Exploring Other Perspectives

The most cautious analysts were assuming roughly flat revenue near US$3.7 billion and only about US$73.7 million of earnings, so compared with the efficiency driven catalyst you have just read about, they sketch a far more constrained recovery path that this latest profit rebound might or might not meaningfully shift.

Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 4 key rewards that could impact your investment decision.

Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

The latest GPUs need a type of rare earth metal called Terbium and there are only 30 companies in the world exploring or producing it . Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any